UPDATE: Wedbush Securities Initiates Coverage On Mirati Therapeutics, Inc. As Key Data Is Around The Corner

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Friday, Wedbush Securities Heather Behanna initiated coverage on Mirati Therapeutics, Inc. (NASDAQ: MRTX) with an Outperform rating and $29.00 price target.In the report, Wedbush Securities noted, “Mirati Therapeutics is focused on development of oncology drugs for targeted patient populations. We believe this approach may lead to robust response rates, streamlined development and accelerated regulatory timelines. Proof-of-concept (POC) data is expected by early 2015 which, if positive, should represent an inflection point for the stock. We believe risk/reward is compelling at these levels and recommend shares of Mirati ahead of these data.”Mirati Therapeutics, Inc. closed on Thursday at $18.92.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!